Skip to main content
Premium Trial:

Request an Annual Quote

IP Update: Recent Patents Awarded to Max Planck, Tokyo Women's Medical University

Premium

Title: RNA Sequence-specific Mediators of RNA Interference

Patent Number: 8,552,171

Filed: Oct. 4, 2010

Lead Inventor: Thomas Tuschl, Max Planck Institute

The invention, the patent's abstract states, relates to a "Drosophila in vitro system which was used to demonstrate that dsRNA is processed to RNA segments 21 [to] 23 nucleotides in length. Furthermore, when these … fragments are purified and added back to Drosophila extracts, they mediate RNA interference in the absence of long dsRNA. Thus, these … fragments are the sequence-specific mediators of RNA degradation. A molecular signal, which may be their specific length, must be present in these … fragments to recruit cellular factors involved in RNAi. This present invention encompasses these … fragments and their use for specifically inactivating gene function. The use of these fragments enables the targeting of specific mRNAs for degradation in mammalian cells, where the use of long dsRNAs to elicit RNAi is usually not practical, presumably because of the deleterious effects of the interferon response. This specific targeting of a particular gene function is useful in functional genomic and therapeutic applications."


Title: Composition for Treatment of Pancreatic Cancer

Patent Number: 8,551,971

Filed: Sept. 13, 2010

Lead Inventor: Toru Furukawa, Tokyo Women's Medical University

The patent, its abstract states, claims a "composition for treating pancreatic cancer … [comprising] a pharmaceutically effective amount of an antisense nucleic acid or siRNA that inhibits expression of at least one gene selected from the group consisting of [the] SON gene, MCM5 gene, WDR5 gene, PBK gene, and CENPA gene. The composition inhibits the expression of a specific gene to provide the effect of inhibiting the proliferation, survival and tumorigenicity of pancreatic cancer cells."

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.